Since its inception in 2020, the CNS Digital Index has been a definitive guide to tracking how leading pharmaceutical companies are harnessing digital tools to transform commercial, clinical, and research operations. Throughout these five years, several organizations have emerged as frontrunners, but only two—Roche and Boehringer Ingelheim—have consistently maintained their positions within the top ten, showcasing their deep commitment to innovation. 

Roche has cemented its place as a digital leader, having secured the top position in 2022 and remaining in the top two across all but one year. This achievement reflects their pioneering use of artificial intelligence and partnerships that streamline data management and enhance patient support systems. Roche’s consistent edge in commercial digital tools has set them apart, allowing them to stay ahead of the curve and lead in a highly competitive landscape. 

Boehringer Ingelheim (BI) shares a similar story of digital success, with a slightly more fluid journey through the rankings. Peaking at third in 2023, BI has leveraged a strong digital focus within its commercial operations, ensuring its place among the Index’s elite. Their strategic approach to digitalization has resulted in repeated top-ten finishes and positioned them as a core player in the evolution of digital healthcare. 

On the other hand, AstraZeneca (AZ) has been a rising force. After an initial absence from the top ten in 2020, AZ steadily climbed the ranks, culminating in a first-place finish in last year’s Index. AstraZeneca’s growth has been fueled by their comprehensive focus on digital advancements across all three subcategories: commercial, clinical trials, and research. This balanced approach to innovation is a prime example of how digital tools can reshape the entire lifecycle of pharmaceutical operations.  

Pfizer has also made its mark, consistently ranking in the top five over the past three years, with notable success in the research subcategory. By employing digital tools to accelerate drug discovery, Pfizer has shown that a strategic commitment to research innovation can drive success and maintain a competitive edge. 

While these companies have become synonymous with digital health innovation, the Index remains a space of continual change, with new companies climbing the ranks each year. Last year, Astellas, Gilead, and Bristol-Myers Squibb (BMS) broke into the top ten for the first time, underscoring the competitive and fast-evolving nature of the CNS Digital Index. Astellas’ 16-spot leap—driven by innovative collaborations—demonstrates just how much ground can be gained through bold digital initiatives.  

Looking to the Future of Digital Innovation in CNS 

As the CNS Digital Index continues to evolve, it’s clear that the future of healthcare is digital. The past five years have been defined by unprecedented growth in AI, patient monitoring tools, and digital therapeutics. This momentum shows no sign of slowing down. With companies like AstraZeneca, Roche, Boehringer Ingelheim, and Pfizer leading the charge, digital innovation is rapidly becoming the norm, not the exception.  

As we look to 2024 and beyond, the race for digital leadership in healthcare will only intensify. Breakthroughs in AI and machine learning, expanded real-world data applications, and the integration of digital health tools into patient care will continue to reshape the landscape. The next generation of top performers in the CNS Digital Index will be those who not only invest in cutting-edge technology but can also adapt quickly to the changing demands of healthcare.  

Whether through partnerships, strategic acquisitions, or in-house innovation, the path forward for all pharmaceutical companies is clear—embrace digital transformation or risk being left behind.